

EXPOSING COMMUNITY ONCOLOGY GAPS: PROMOTING MRD TESTING FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Monique Dawkins, EdD¹, Lorna Lucas, MSM¹, Leigh Boehmer, PharmD, BCOP¹

¹Association of Community Cancer Centers, Rockville, MD, USA




Context

Minimal residual disease (MRD) has been utilized by many academic providers to determine appropriate treatment and maintenance options for patients. Community oncology providers, however, may require additional education on the advancements in care and benefits of MRD testing for adult patients with ALL.

Participants

13 Multidisciplinary Advisory Committee Members and Visiting Faculty including a patient advocacy organization and patient led this project.



Objective

The Association of Community Cancer Centers (ACCC) led a national initiative, with an emphasis on integration of MRD testing, to improve the treatment and management of adult patients diagnosed with ALL in community oncology practices.

Main Outcomes

6 Key Areas that need further education were identified:

1. Initial Diagnostic Workup
2. Shared Decision-Making
3. MRD Testing
4. Patient Access
5. Cost and Reimbursement
6. Side-Effect Management

Design

Build Advisory Committee



Conduct Landscape Analysis



Develop Peer-to-Peer Learning Resources



Educate and Disseminate Resources



Results

Resources, including a dedicated ALL provider portal, a four-part blog series, and three webinars (2 webinars, specifically addressed the prognostic and treatment selection- related importance of MRD testing) were developed based on the results of the environmental scan.

Conclusions

The resources created represent comprehensive educational material that are useful to both providers and patients. They are available on-demand.

ACKNOWLEDGEMENTS

This project was sponsored by



In partnership with



CONTACT: Monique Dawkins, mdawkins@acc-cancer.org

www.acc-cancer.org